Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Blood (2023) 141 (23): 2841–2852.

https://doi.org/10.1182/blood.2022018885

Published: 2023

Includes: Supplemental data

Journal Articles

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

Teru Hideshima, Constantine Mitsiades, Hiroshi Ikeda, Dharminder Chauhan, Noopur Raje, Gullu Gorgun, Hiromasa Hideshima, Nikhil C. Munshi, Paul G. Richardson, Daniel R. Carrasco, Kenneth C. Anderson

Blood (2010) 115 (18): 3772–3775.

https://doi.org/10.1182/blood-2010-02-270082

Published: 2010

Includes: Supplemental data

Journal Articles

Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells

Teru Hideshima, Hiroshi Ikeda, Dharminder Chauhan, Yutaka Okawa, Noopur Raje, Klaus Podar, Constantine Mitsiades, Nikhil C. Munshi, Paul G. Richardson, Ruben D. Carrasco, Kenneth C. Anderson

Blood (2009) 114 (5): 1046–1052.

https://doi.org/10.1182/blood-2009-01-199604

Published: 2009

Includes: Supplemental data

Journal Articles

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

Mariateresa Fulciniti, Pierfrancesco Tassone, Teru Hideshima, Sonia Vallet, Puru Nanjappa, Seth A. Ettenberg, Zhenxin Shen, Nipun Patel, Yu-tzu Tai, Dharminder Chauhan, Constantine Mitsiades, Rao Prabhala, Noopur Raje, Kenneth C. Anderson, David R. Stover, Nikhil C. Munshi

Blood (2009) 114 (2): 371–379.

https://doi.org/10.1182/blood-2008-11-191577

Published: 2009

Journal Articles

TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application

Rao Prabhala, PhD, Dheeraj Pelluru, Mariateresa Fulciniti, Puru Nanjappa, Harsha K. Prabhala, Nithya S. Prabhala, Constantine Mitsiades, Yu-Tzu Tai, Irene Ghobrial, Paul Richardson, Konstantinos Lefkimmiatis, John F. Daley, Yvonne A. Efebera, Kenneth C. Anderson, MD, Nikhil C. Munshi

Blood (2008) 112 (11): 2737.

https://doi.org/10.1182/blood.V112.11.2737.2737

Published: 2008

Journal Articles

Preclinical Evaluation of CRx-501, a Potent Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma

Richard J Rickles, Ph.D., Laura Pierce, Thomas Giordano, William Avery, Melissa Farwell, David Crowe, Winnie F. Tam, Ph.D., Mei Chen, Ph.D., Vikram Kansra, PhD, Douglas W. McMillin, BSc, PhD, Kenneth C Anderson, MD, Constantine Mitsiades, M.D., Ph.D., Margaret S. Lee, PhD

Blood (2008) 112 (11): 252.

https://doi.org/10.1182/blood.V112.11.252.252

Published: 2008

Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

Blood (2008) 112 (11): 1742.

https://doi.org/10.1182/blood.V112.11.1742.1742

Published: 2008

Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study

Blood (2008) 112 (11): 92.

https://doi.org/10.1182/blood.V112.11.92.92

Published: 2008

Journal Articles

Adenosine A2A Receptor Agonism and PDE Inhibition: A Synergistic Multi-Target Mechanism Discovered through Systematic Combination Screening in Multiple Myeloma

Richard J Rickles, Ph.D., Laura Pierce, Thomas Giordano, Winnie F. Tam, Ph.D., Douglas W. McMillin, BSc, PhD, Kenneth C. Anderson, MD, Constantine Mitsiades, M.D., Ph.D., Margaret S Lee, Ph.D

Blood (2008) 112 (11): 847.

https://doi.org/10.1182/blood.V112.11.847.847

Published: 2008

Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.

Blood (2007) 110 (11): 187.

https://doi.org/10.1182/blood.V110.11.187.187

Published: 2007

Journal Articles

Defibrotide Counteracts the Modifications of Anti-Thrombotic Phenotype of Endothelial Cells Induced by Thalidomide.

Cinara Echart, PhD, Barbara Graziadio, Cinzia Repice, Mario Boccadoro, MD, Antonio Palumbo, MD, Constantine Mitsiades, MD, Kenneth Anderson, MD, Paul Richardson, MD, Massimo Iacobelli, MD

Blood (2007) 110 (11): 2502.

https://doi.org/10.1182/blood.V110.11.2502.2502

Published: 2007

Journal Articles

Co-Culture of Myeloma and Endothelial Cells: Defibrotide Downregulates Heparanase and Pro-Angiogenic Growth Factors.

Cinara Echart, PhD, Maria Distaso, Laura Ferro, MD, Mario Boccadoro, MD, Antonio Palumbo, MD, Constantine Mitsiades, MD, Kenneth Anderson, MD, Paul Richardson, MD, Massimo Iacobelli, MD

Blood (2007) 110 (11): 2513.

https://doi.org/10.1182/blood.V110.11.2513.2513

Published: 2007

Journal Articles

Pharmacogenomics Study of Biological Pathways Related to Bortezomib Activity in Myeloma.

George Mulligan, Barb Bryant, Steven Roels, Andrew Bolt, Yan Meng, Erik Koenig, Anthony Boral, Dixie-Lee Esseltine, Kenneth A. Anderson, Peter Leif Bergsagel, Pieter Sonneveld, Annemiek Broyl, Constantine Mitsiades, Wee-Joo Chng, Paul G. Richardson, William Trepicchio

Blood (2007) 110 (11): 392.

https://doi.org/10.1182/blood.V110.11.392.392

Published: 2007

Journal Articles

Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma.

Blood (2007) 110 (11): 256.

https://doi.org/10.1182/blood.V110.11.256.256

Published: 2007

Journal Articles

Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications.

Teru Hideshima, MD, PhD, Noopur Raje, MD, Ruben Carrasco, MD, PhD, Hiroshi Ikeda, MD, PhD, Yutaka Okawa, MD, PhD, Tanyel Kiziltepe, PhD, Sonia Valet, MD, Samantha Pozzi, MD, Dharminder Chauhan, PhD, Constantine Mitsiades, MD, PhD, Klaus Podar, MD, PhD, Yu-Tzu Tai, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 670.

https://doi.org/10.1182/blood.V110.11.670.670

Published: 2007

Journal Articles

Hedgehog Pathway as a Potential Therapeutic Target in Multiple Myeloma.

Simona Blotta, MD, Joeseph Negri, Purushothama Nanjappa, Anne-Sophie Moreau, MD, Rao Prabhala, PhD, Masood Shammas, PhD, Dheeraj Pelluru, PhD, Douglas McMillin, PhD, Yu-Tzu Tai, PhD, Pierfrancesco Tassone, MD, Kenneth C. Anderson, MD, Constantine Mitsiades, MD, PhD, Nikhil C. Munshi, MD

Blood (2007) 110 (11): 672.

https://doi.org/10.1182/blood.V110.11.672.672

Published: 2007

Journal Articles

High-Resolution Assessment of Gains and Losses of Chromosomes in Patients with Multiple Myeloma Treated with Bortezomib.

Hadi Danaee, Barb Bryant, Steve Roels, Dave Lichter, Eric Koening, William L. Trepicchio, Anthony Boral, Paul Richardson, Yan Meng, Peter Leif Bergsagel, Pieter Sonneveld, Annemiek Broyl, Constantine Mitsiades, Wee-Joo Chng, Kenneth Anderson, George Mulligan

Blood (2007) 110 (11): 4763.

https://doi.org/10.1182/blood.V110.11.4763.4763

Published: 2007

Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study.

Blood (2007) 110 (11): 2714.

https://doi.org/10.1182/blood.V110.11.2714.2714

Published: 2007

Journal Articles

A Phase I/II Trial on Melphalan, Prednisone, Thalidomide and Defribotide Combination in Relapsed/Refractory Multiple Myeloma Patients.

Antonio Palumbo, MD, Alessandra Larocca, MD, Cecilia Rus, MD, Francesca Gay, MD, Davide Rossi, MD, Patrizia Pregno, MD, Patrizia Falco, MD, Ilaria Avonto, MD, Valeria Magarotto, MD, Federica Cavallo, MD, Massimo Iacobelli, MD, Gianluca Gaidano, MD, Constantine Mitsiades, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Mario Boccadoro, MD

Blood (2007) 110 (11): 2715.

https://doi.org/10.1182/blood.V110.11.2715.2715

Published: 2007

Journal Articles

Antimyeloma Efficacy of Plitidepsin (Aplidin®): From Bench to the Bedside.

Blood (2007) 110 (11): 1178.

https://doi.org/10.1182/blood.V110.11.1178.1178

Published: 2007

NARROW

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application

Preclinical Evaluation of CRx-501, a Potent Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study

Adenosine A2A Receptor Agonism and PDE Inhibition: A Synergistic Multi-Target Mechanism Discovered through Systematic Combination Screening in Multiple Myeloma

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.

Defibrotide Counteracts the Modifications of Anti-Thrombotic Phenotype of Endothelial Cells Induced by Thalidomide.

Co-Culture of Myeloma and Endothelial Cells: Defibrotide Downregulates Heparanase and Pro-Angiogenic Growth Factors.

Pharmacogenomics Study of Biological Pathways Related to Bortezomib Activity in Myeloma.

Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma.

Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications.

Hedgehog Pathway as a Potential Therapeutic Target in Multiple Myeloma.

High-Resolution Assessment of Gains and Losses of Chromosomes in Patients with Multiple Myeloma Treated with Bortezomib.

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study.

A Phase I/II Trial on Melphalan, Prednisone, Thalidomide and Defribotide Combination in Relapsed/Refractory Multiple Myeloma Patients.

Antimyeloma Efficacy of Plitidepsin (Aplidin®): From Bench to the Bedside.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only